Corante

About this Author
Derek Lowe
Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
MedChem Buzz
Kilomentor
On Pharma
A New Merck, Reviewed
Liberal Arts Chemistry
One in Ten Thousand
Electron Pusher
Periodic Tabloid
All Things Metathesis
C&E News Blog
Propter Doc
Chemiotics II
The Chemical Notebook
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
Chirality
BBSRC/Douglas Kell
ChemBark
Drug Discovery Opinion
Realizations in Biostatistics
Chemjobber
Pharmalot
WSJ Health Blog
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Useful Chemistry
Chiral Jones
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Totally Synthetic
Fragment Literature
The F- Blog
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Carbon-Based Curiosities
Experimental Error
Business|Bytes|Genes|Molecules
Eye on FDA
Sigma-Aldrich ChemBlogs
Chemical Forums
Depth-First
Symyx Blog
P212121
ChemCafe
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
A Scientist's Life
Speculist
Cosmic Variance
The Capsule
Zeroth Order Approximation
Biology News Net


Medical Blogs
Med Tech Sentinel
DB's Medical Rants
Science-Based Medicine
GruntDoc
The Health Care Blog
Respectful Insolence
Black Triangle
Diabetes Mine


Economics and Business
Marginal Revolution
Arnold Kling
The Volokh Conspiracy
Knowledge Problem
The Stalwart


Politics / Current Events
Virginia Postrel
Tinkerty Tonk
Instapundit
Megan McArdle
Mickey Kaus
Colby Cosh
Alien Corn
No Watermelons


Belles Lettres
Two Blowhards
Critical Mass
Arts and Letters Daily
God of the Machine
Armavirumque
About Last Night
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« You'd Think It Was An Election Year or Something | Main | Primum Non Nocere, Eh? »

June 21, 2004

Le Dernier Cri

Email This Entry

Posted by Derek

Mentioning all the nanostructure papers in the journals brings up the topic of fashions in chemistry. We've got 'em, all right. Waves like this tend to wash over the literature every few years. (I can only speak for organic chemistry, but I assume that it's the same in the other disciplines.)

For example, only in the last couple of years have we begun to escape from the olefin metathesis craze. That's a useful reaction, and I can't make fun of it on its face. But a few years ago, it seemed that everyone with two alkenes in their lab was finding a way to get them in the same flask with some Grubbs catalyst or whatnot. People looked at the reaction and said "Hey, that's neat. I could do that", and they did.

Of course, people also look at these things and think "Hey, that's neat. I could publish that" or "Hey, that's neat. I could get funded for that", and those reasons carry a lot of weight. So journal editors and the reviewers at granting agencies carry some responsibility for these fads, but they're just as human as the rest of us. Most of the time.

These bursts of activity can serve a useful purpose. The state of the art advances rapidly when everyone's trying to improve it, as you'd figure. The best examples of waves of interest have a can-you-top-this quality in them; the worst have a bunch of chemists just doing the same thing because everyone else is doing it.

There are even fashionable molecules, ones that have been synthesized over and over again, because they come in handy to show that your new synthetic method is good for something. (That's not a line of argument that I find very compelling, but it's a common one.) An insect attractant called brevicomin is a good example. I'm sure that I've seen six or eight synthetic routes to that, and it's not like I've been collecting them, either. Twenty years or so ago, the jokes were about a molecule called cis-jasmone, which turned up over and over again when someone wanted to prove their synthetic moves.

But since we're talking about fashion, I should note that the whole field of natural product total synthesis isn't as fashionable as it used to be. That's a larger topic worth a post of its own, but it's something that's had its practioners a bit worried and defensive the last few years.

Comments (2) + TrackBacks (0) | Category: The Scientific Literature


COMMENTS

1. The Un-Candidate on June 21, 2004 10:37 AM writes...


What are you talking about!?! It's as relevant as ever! We can solve all sorts of problems through total synthesis!

Oh, wait...

Permalink to Comment

2. Derek Lowe on June 21, 2004 3:57 PM writes...

As it turns out, I was way too conservative in my estimate in paragraph 5. A quick look through the literature shows at least twenty syntheses of endo- or exo-brevicomin.

I remember hearing a professor in the field express scorn in 1985 at yet another synthesis that had appeared, but clearly a dozen more have shown up since then. It seems that if you have a route to chiral hydroxyaldehydes, you are required by law to synthesize brevicomin.

Permalink to Comment


EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
Academia and Industry, Suing Each Other
Let's Start Off the Meeting With An Ad, OK?
The Academic-Industrial Collaboration in Drug Discovery Panel: Today
Glass Structure, Atom by Atom
How the Andrulis Paper Got Published
AstraZeneca in Waltham
Fluorine NMR: Why Not?
AstraZeneca Layoffs and Closings